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goal was highest when increasing the statin dose (0.406), fol-
lowed by changing to a different statin (0.387), adding an addi-
tional therapy to the statin (0.320), not changing therapy
(0.306), and changing the statin to an alternative therapy
(0.111). The decision with the lowest average cost-effective ratio
was increasing the statin dose ($331.75). Incremental analysis
showed the cost of getting one more patient to goal was the
lowest for changing to a different statin ($126.85), followed by
increasing the statin dose ($173.16), and changing to an alter-
native therapy ($868.38). Sensitivity analysis found robust
results for the probabilities of reaching goal. Cost data was sen-
sitive between the decisions of increasing statin dose and chang-
ing statins. CONCLUSION: The most cost-effective decisions in
this study were to increase the statin dose or change to a differ-
ent statin.
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OBJECTIVES: Statin therapy reduces the rate of cardiovascular
disease, but high costs in combination with a large population
eligible for treatment ask for priority setting. Although trials
agree on the size of the beneﬁt, economical analyses of statins
report contradictory results. METHODS: We reviewed cost
effectiveness analyses comparing statins with no treatment and
sought to synthesize cost effectiveness ratios for categories of risk
of coronary heart disease and age. Data Sources: Medline, the
British National Health Service Economic Evaluation database
and authors’ reference lists. We searched for studies comparing
statins to no treatment for the prevention of cardiovascular
disease in adult male populations. Reviews and meta-analyses
were excluded. Studies needed to present cost per Years of Life
Gained/Saved (YLS, YLG) as outcome. Studies comparing statins
with other statins, or other medicaments were excluded.
RESULTS: Twenty-four studies were included, yielding 216 cost
effectiveness ratios. As expected, cost effectiveness ratios increase
with decreasing absolute risk. However after stratiﬁcation by
absolute risk, heterogeneity of CER is large with outcomes
varying from savings to US$ 59,000 per life year saved in the
highest risk category and from US$6500 to 490,000 in the lowest
risk category Disagreement increased at lower levels of risk.
Absolute risk was the only signiﬁcant predictor of cost effec-
tiveness ratios. Various signiﬁcant interactions with absolute risk
were found. CONCLUSION: Statin therapy is cheap for high
levels of risk, but discrepancies exist at lower levels of risk.
Although the cost-effectiveness of statins depends mainly on
absolute risk, factors like age, funding source and methodologi-
cal variables might be behind the ample remaining heterogene-
ity of the CER after adjusting for absolute risk. Economic
analyses need to increase their transparency to reduce their 
vulnerability to bias and increase their reproducibility.
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OBJECTIVES: To compare the cost-effectiveness of amiodarone,
atrial septal pacing, amiodarone plus atrial septal pacing, in
addition to standard therapy with beta-blockers, to standard
therapy alone to prevent postoperative atrial ﬁbrillation in
patients undergoing open-heart surgery. METHODS: A piggy-
back cost-effectiveness analysis of a randomized, placebo-
controlled, 2 ¥ 2 factorial trial was conducted from a hospital
perspective. Charges were converted to costs using cost-to-
charge ratios. For the cost-effectiveness analysis, a joint distrib-
ution of costs and effectiveness was performed using the
nonparametric bootstrap method. RESULTS: The incidence of
postoperative atrial ﬁbrillation was 38%, 28%, 40%, and 16%
with standard care, amiodarone, atrial septal pacing, and amio-
darone plus atrial pacing, respectively (standard care vs. amio-
darone + pacing, p = 0.047; pacing vs. amiodarone + pacing, p
= 0.04). Total costs (mean ± SD) were $27,026 ± 30,226 in the
standard of care, $22,725 ± 17,661 in the amiodarone, $33,868
± 60,309 in the atrial septal pacing and $18,697 ± 8,174 in the
amiodarone plus atrial septal pacing groups (p = 0.27). In the
joint distribution cost-effectiveness analysis, compared to stan-
dard of care, the probability of lower cost but higher effect (supe-
riority) was 67% for amiodarone, 15% for atrial septal pacing,
and 97% for amiodarone plus atrial septal pacing. In multivari-
ate analysis, preoperative beta-blockers and amiodarone were
negatively associated with hospital costs (p < 0.05). CONCLU-
SIONS: Data suggest that amiodarone and amiodarone plus
atrial septal pacing are cost-effective compared to standard
therapy alone. Additional comparative studies between these
strategies are warranted to conﬁrm these ﬁndings.
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OBJECTIVES: To assess the use and cost of antilipemic drugs in
NHG institutions. METHODS: Dispensing data for antilipemic
drugs for various NHG institutions from Jan–Sept 2003 was
extracted and analysed using WHO ATC/DDD methodology
(version 2004). Setting: Primary care: NHG Polyclinics (NHGP).
Secondary care: Alexandra Hospital (AH) and Tan Tock Seng
Hospital (TTSH)—the latter has large general medicine and 
geriatric departments. Tertiary care: National University Hospi-
tal (NUH)—which has a large cardiac department and an active
lipid clinic. RESULTS: Statins accounted for 90% (88–92%)
whereas ﬁbrates accounted for 10% (8–12%) of total DDDs.
Lovastatin and simvastatin predominated the antilipemic drugs
use (83% of total DDDs). Although atorvastatin and pravas-
tatin’s usage was less than 7% of total DDDs, they accounted
for almost 50% of the total cost for antilipemic drugs. The total
usage and cost of antilipemic drugs were highest in NHGP. 
Atorvastatin and pravastatin were used more commonly in NUH
and TTSH (22% & 17% respectively) and resulted in higher
(2–3 times) average daily cost as compared to AH & NHGP (2%
for both institutions). The analysis also revealed that NUH &
NHGP have a higher average daily cost of bile acid sequestrants
and nicotinic acid derivatives respectively due to the use of more
expensive agents in these groups of drugs. CONCLUSIONS:
Generally, the utilisation proﬁle of the broad classes of
antilipemic drugs was similar across the four institutions. Statins
were the leading antilipemic drugs followed by ﬁbrates. Some
institutions used more expensive antilipemic drugs as compared
to the others. This has signiﬁcant cost implication to patients and
institutions. A closer analysis of patterns of antilipemic drug
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usage would be needed to identify the reasons and desired out-
comes for the use of these agents. This would also potentially
derive initiatives that might help rationalise the prescription of
these agents.
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OBJECTIVE: Clinical trials have demonstrated moderate thera-
peutic efﬁcacy for orlistat and sibutramine, with patients losing
between 5–10% of initial body weight. Due to the cost of orlis-
tat and sibutramine and moderate efﬁcacy, Kansas Medicaid
chose to use prior authorization to control expenditures on anti-
obesity agents. The objective of this study was to determine if
differences exist in cost and effect between patients who received
PA approval for anti-obesity therapy and those who did not.
METHODS: A retrospective, cohort study was designed in
which patients were divided into those that received PA approval
for sibutramine or orlistat and those that did not. The payer per-
spective was used in this study. Cost data included the total direct
costs incurred by the Medicaid program including medications,
physician ofﬁce visits, hospital admissions, and administrative
costs of the PA program. Effectiveness therapy was measured by
the probability of patients achieving greater than 5% loss of
initial weight. Independent sample t-tests were used to determine
if differences exist between mean costs and effectiveness between
the alternatives. RESULTS: Patients who received PA approval
for orlistat/sibutramine incurred $16,730 ± $20,185 in average
total costs over the study time period compared to $12,527 ±
$18,702 for patients who did not (p = 0.02). Average initial
weights and BMIs for patients who received drug therapy were
286 pounds and 43.4kg/m2 respectively, while patients who
didn’t had average initial weights of 255 pounds and BMI of
38.9kg/m2. Patients who received anti-obesity therapy met the
effectiveness goal 33% of the time, compared to 5% of the time
for a patient who didn’t (p < 0.001). CONCLUSION: The
average cost per Medicaid beneﬁciary was $4203 higher for
those patients who received prior authorization approval for
anti-obesity therapy compared to those who did not. However,
patients also had a signiﬁcantly higher probability of losing
weight.
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OBJECTIVE: Quality of Life instruments may be generic or
more disease speciﬁc. We were interested in disease speciﬁc
quality of life in patients following aortic valve replacement.
METHODS: We surveyed 743 patients following aortic valve
replacement surgery. The survey instruments were the SF-36 and
the Minnesota Living with Heart Failure Questionnaires.
MLwHF scores are computed by adding scores ranging from 
0 to 5 on 21 questions, yielding total summary scores of 0 to
105 with higher scores indicating poorer quality of life. All
patients were also part of an adult cardiac database that included
prospectively collected information on demographics, diagnosis
and surgical course. One-way analysis of variance (ANOVA)
tests were used to compare continuous demographic, pre-
operative, operative, and post-operative variables, and MLwHF
scores across different valve types. RESULTS: Three hundred
twenty-nine patients (43%) returned surveys. There were no dif-
ferences in age, gender or valve type received between respon-
ders and non-responders. Of the respondents, 226 were male and
103 were female. The average age was 61.8 (standard deviation
= 13.9, range 15 to 90). The majority of patients [222 (67.48%)]
received the Medtronic Freestyle stentless bioprosthetic valve, 16
(4.86%) received stented bioprosthetic valves, 56 (17.02%)
received mechanical valves, and 13 (3.95%) received homo-
grafts. The MLwHF found homograft recipients to have on
average poorer QoL (as reﬂected by higher MLwHF scores), but
these differences were not signiﬁcant. No signiﬁcant differences
were seen in MLwHF scores across valve types. Patient Mean &
Standard Deviation scores for respective categories: Physical
10.45, 10.43; Emotional 5.04, 6.23; Total 23.28, 22.71. CON-
CLUSIONS: Our study suggests that 5 to 10 years after AVR no
single valve type has a clear QoL advantage and conﬁrms pre-
vious reports that age-matched population QoL norms can be
achieved in many domains. Postulated advantages and dis-
advantages of stentless valves did not seem to have any net effect
on QoL.
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OBJECTIVE: To analyze the construct validity, criterion valid-
ity, and the acceptance and understanding of the EQ-5D in
patients with acute coronary syndromes (ACS). METHODS: All
ACS-diagnosed patients discharged from a university-afﬁliated
hospital during a 3-year period were mailed a questionnaire that
included the EQ-5D and the SF-8. The EQ-5D includes a 100-
point visual analogue scale (VAS) to measure self-reported
current health-state and ﬁve items measuring mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression. Also
included were disease severity measures [Duke Activity Status
Index (DASI), cardiac symptom count (SC), patient-perceived
cardiac disease severity], comorbidity measures (Charlson
comorbidity index, total medication count), and other demo-
graphic and disease-related items. RESULTS: Of 1217 patients,
490 (40.3%) responded. Patients averaged 65.2 (± 11.3) years
of age; 71.0% male; 91.9% Caucasian; 64.3% history of MI.
Acceptance and understanding appeared high with only
0.2%–0.4% of EQ-5D items and 8% of the VAS unanswered.
Correlations between the VAS score and DASI/SC/perceived
severity were rs = 0.741/rs = -0.615/rs = -0.455 (all p < 0.0001).
Levels of responses to EQ-5D items and the VAS score were sig-
niﬁcantly better for patients with very mild/mild perceived
disease severity compared to severe/very severe, and for patients
with a DASI ≥ 18 compared to a DASI < 18. VAS score and 
SF-8 subscale score correlation coefﬁcients ranged from
0.526–0.764 (all p < 0.0001). Signiﬁcant differences were
observed between the response level of individual EQ-5D items
and scores of comparable SF-8 subscales. The nine most common
health states were identiﬁed based on the ﬁve EQ-5D item scores.
As health status diminished there was a decline in the VAS, DASI
and satisfaction with current health state, and an increase in the
perceived severity, comorbidity score, SC, and medication count.
